Ambit Biosciences (AMBI) announces the presentation of data from a Phase 2 study of the FLT3...

|About: Ambit Biosciences Corp (AMBI)|By:, SA News Editor

Ambit Biosciences (AMBI) announces the presentation of data from a Phase 2 study of the FLT3 inhibitor quizartinib and says that based on the "positive" results and "ongoing discussions with the FDA," the company plans to initiates a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia in H1 2014. Shares +7.35% premarket. (PR)